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A New Mutation in the Promoter Region of the PAX8 Gene
Causes True Congenital Hypothyroidism
with Thyroid Hypoplasia in a Girl with Down’s Syndrome
Pia Hermanns,1 Scott Shepherd,2 Mohamed Mansor,3 John Schulga,3
Jez Jones,2 Malcolm Donaldson,2 and Joachim Pohlenz1
Background: Thyroid dysfunction is common in newborn infants with Down’s syndrome (DS), but defects
causing classic thyroid dysgenesis (TD) with permanent congenital hypothyroidism (CH) have not been
described.
Objective: We studied a girl with DS and CH who had a mutation in the promoter sequence of the PAX8 gene.
Results: A female infant was found to have trisomy 21 and CH, with a venous thyrotropin (TSH) of >150 mU/L
and a free thyroxine (fT4) of 15.1 pmol/L (day 12). Thyroid peroxidase antibodies and thyroglobulin antibodies
were elevated. Scintigraphy showed normal uptake, but ultrasound identified a small gland with heterogenous
echotexture and cystic changes. Sequence analysis of the PAX8 gene revealed a new heterozygous maternally
inherited mutation (-3C>T) close to the transcription initiation site. Electromobility shift assay studies of the wild
type and the mutant PAX8 sequence incubated with nuclear extracts from PCCL3 cells exhibited that the sequence
at position -3 is not involved in specific protein binding. However, the mutant PAX8 promoter showed a
significantly reduced transcriptional activation of a luciferase reporter gene in vitro tested in HEK, PCCL3, as well
as in HeLa cells, indicating that this mutation is very likely to lead to reduced PAX8 expression.
Conclusions: The persistent CH in this patient with DS is likely to be attributable to the diminished PAX8
expression due to a new heterozygous mutation in the PAX8 promoter sequence. Our case shows that true CH may
occur in DS, as in the general population. Furthermore, it is possible that the trisomy 21 itself may have resulted in
a more severe phenotypic expression of the PAX8 mutation in the child than the mother.
Introduction
Congenital hypothyroidism (CH) is the most commoninborn endocrine disorder and is usually caused by either
thyroid dysgenesis (TD) or thyroid dyshormonogenesis. In
the majority of cases (80–85%), CH is due to TD, which
usually takes the form of an absent or ectopic gland, re-
presenting a defect in thyroid migration (1). More rarely, TD
results in a hypoplastic thyroid gland in situ, a phenotype
accounting for about 10% of all cases of CH (2). The mo-
lecular mechanisms leading to TD are mostly unknown. So
far, only a few single gene mutations have been identified
when the known candidate genes (thyroid transcription factors
1 and 2 (TTF1 and TTF2), the thyrotropin-receptor (TSHR), the
NK2 transcription factor related locus 5 (NKX2.5), and the
paired box gene 8 (PAX8)) of individuals with TD were in-
vestigated (3). One of those candidate genes for TD—the
PAX8 gene—is of particular interest, since mutations in this
gene can be associated with a highly variable phenotype
presenting with TD or even a normal thyroid gland within the
same family (4), raising the possibility of incomplete pene-
trance or the presence of genetic or nongenetic modifiers (5).
Recently, we identified a mutation in the promoter sequence
of the PAX8 gene to be causative for TD in a girl who also had
a NKX2.5 gene mutation (6). We have therefore begun to
analyze the promoter sequence of the PAX8 gene in other
patients with TD who did not harbor a mutation in the coding
regions of the known candidate genes for TD.
Down’s syndrome (DS) is the most common chromosomal
disorder with an adjusted prevalence in the United Kingdom
of 1.08 per 1000 live births (7). Thyroid dysfunction is com-
mon, particularly acquired autoimmune thyroiditis (8). In
newborn infants, thyrotropin (TSH) elevation is often seen
and is typically transient in nature (9), possibly reflecting
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altered regulation of the thyroid axis (10). However, classic
CH with dysgenesis is not an established feature in DS.
We describe a new mutation close to the transcription
initiation site of the PAX8 gene in a girl with DS and thyroid
hypoplasia. In vitro studies show that this mutation causes a
reduction in the PAX8 gene expression level, and is therefore
very likely to be causative.
Case Report
Our patient, a female, was born after 40 weeks of gestation
by spontaneous vaginal delivery as a breech presentation to a
24-year-old mother with no history of thyroid disease fol-
lowing a normal pregnancy. Dysmorphic features consistent
with DS were noted shortly after birth, and karyotype exam-
ination confirmed trisomy 21. A cardiac ultrasound showed a
large perimembranous ventricular septal defect (VSD), a se-
cundum atrial septal defect (ASD), and a patent ductus arte-
riosus (PDA). Elective repair was planned, but at 35 days, the
baby was admitted with failure to thrive and cardiac failure.
She was commenced on nasogastric feeding and regular di-
uretics, and subsequently underwent Dacron patch closure of
her VSD, a direct suture closure of her ASD, and a ligation of
her PDA at the age of 69 days. She was readmitted on day 106
with respiratory distress and stridor, and was found to have
supraglottic edema consistent with reflux laryngitis. A barium
swallow confirmed significant gastroesophageal reflux, and
she underwent fundoplication and gastrostomy insertion at
day 133. Her gastrostomy has remained in situ since dis-
charge, and she required readmission at the age of 2.25 years
for open jejunostomy and reinsertion of the gastrostomy.
Thyroid features
Newborn blood spot screening on day 5 demonstrated hy-
perthyrotropinemia at 43.8 mU/L in whole blood (normal
<8 mU/L). At the time of referral (day 12), she was noted to be
constipated and suffering from prolonged neonatal jaundice,
and a venous blood sample showed a serum TSH of >150 mU/
L (normal 0.72–13.1 mU/L) and a normal free thyroxine (fT4)
of 15.1 pmol/L (normal 8–25 pmol/L) indicating compensated
primary CH. Thyroid peroxidase antibodies (TPOAb) were
elevated at 409 IU/mL (normal <50 IU/mL) consistent with
transplacental transfer of maternal thyroid antibodies. Un-
fortunately, however, there is no record of maternal thyroid
function tests from this time. The infant was commenced on
levothyroxine at 25 and 50lg on alternate days. Thyroid
function tests were repeated on day 28 and demonstrated a good
response to levothyroxine with a serum TSH of 11.03 mU/L
(normal 0.72–13.1 mU/L), a fT4 of 31.9 pmol/L (normal 8–
25 pmol/L), and a free triiodothyronine (fT3) of 2.2 nmol/L
(normal 0.9–2.8 nmol/L). Her thyroglobulin was 103 ng/mL
(normal < 55 ng/mL), and thyroglobulin antibodies were
< 20 IU/L (normal < 40 IU/L). In light of these results, her
levothyroxine dose was adjusted to 25 lg daily.
Combined ultrasound and radioisotope imaging of the
thyroid gland was performed on day 14. An ultrasound
showed a small gland with a right lobe volume of 0.44 mL, a
left lobe volume of 0.31 mL, and a combined volume of
0.76 mL (reference range 1.0–3.3 mL) (6). The gland was very
heterogeneous in echotexture with many small and two large
cystic areas. The isthmus appeared bulky, measuring 0.26 mL.
A radioisotope thyroid scan after intravenous injection of
10 MBq of pertechnetate showed a normal uptake in an ap-
parently normal bilobed thyroid gland in a normal position.
At 1.35 years, her TSH was very elevated at >150 mU/L
(normal 0.46–8 mU/L) with a fT4 of 9.3 pmol/L (normal 9–
23 pmol/L) despite treatment with 43.75lg of levothyroxine
daily, suggestive of compliance difficulties. The levothy-
roxine dose was increased to 50lg daily, and her thyroid
function remained normal thereafter.
At 3.8 years, the dose of levothyroxine was reduced to
25 lg daily to establish whether the child’s CH was transient
or permanent in nature. Six weeks later, her TSH had risen to
53.61 mU/L (reference range 0.35–5.5 mU/L) with a fT4 of
12.1 pmol/L (reference range 9–24 pmol/L) confirming the
persistence of primary hypothyroidism, and the levothy-
roxine dose was increased back to 50 lg daily.
At the same time, the mother was found to have a TSH of
16.13 mU/L, a fT4 of 12.6 pmol/L, and TPOAb >1000 IU/
mL, and treatment with levothyroxine was initiated.
After obtaining informed written consent, molecular ge-
netic studies were conducted.
Material and Methods
Subjects, DNA amplification, and DNA sequencing
We obtained written informed consent from all available
family members to participate in the clinical and genetic
studies. Genomic DNA from blood samples was isolated
utilizing the Puregene Blood Core Kit B (Qiagen, Hilden,
Germany). The coding sequences of the candidate genes for
TD, as well as the promoter sequence of the PAX8 gene, were
amplified by polymerase chain reaction (PCR; conditions and
primer sequences for mutational screening of TSHR, PAX8,
TTF1, TTF2, and NKX2.5 can be supplied upon request),
purified with the HiYield PCR Clean-up/Gel Extraction Kit
(Su¨d-Laborbedarf GmbH, Gauting, Germany), and then se-
quenced with BigDye terminator v.3.1 purified by ethanol
precipitation and analyzed using an automated sequencing
system (3130 Avant Genetic Analyzer, Applied Biosystems,
Weiterstadt, Germany).
Constructs and mutagenesis
To study the consequence of the PAX8 promoter muta-
tion, a 1130 bp fragment upstream of the ATG of the PAX8
gene was amplified and cloned upstream of the luciferase
gene of the pGL3 basic vector (Promega, Madison, WI).
This promoter construct (PAX8proWT) was a gift from Dr.
Peter Kopp (Northwestern University, Chicago, IL). To
construct the PAX8 promoter mutation (PAX8proMUT),
we used the Quick Change Mutagenesis XL kit (Agilent
Technologies, La Jolla, CA) and the primers PAX8_-3-F:
5¢-GGT GAT GCC GGG TGA ATG GGA ACA AAC-3¢
and PAX8_-3_R: 5¢-GTT TGT TCC CAT TCA CCC GGC
ATC ACC-3¢ respectively. All constructs were verified by
sequencing.
Cell culture and transfection
HeLa and HEK cells were grown in PAN 401 medium
supplemented with 10% fetal bovine serum (FBS; PAN
Biotech GmbH, Aidenbach, Germany) and 1% penicillin-
streptomycin (PAN Biotech GmbH) at 37C in a humidi-
fied chamber with 5% CO2. PCCL3 cells were a gift from
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Dr. Annette Altmann (Clinical Cooperation Unit, Nuclear
Medicine, Heidelberg, Germany), and were grown in Ham’s
F12 K medium supplemented with 10% FBS, 1% penicillin-
streptomycin (PAN Biotech GmbH), 10 ng/mL somatostatin,
10 ng/mL Glys-His-Lys, 5lg/mL transferin, 10 nM hydro-
cortisone, 10 lg/mL insulin, and 10 mU/mL TSH (Sigma-
Aldrich, St. Louis, MO) at 37C in a humidified chamber with
5% CO2. Twelve hours before transfection, cells were tryp-
sinized and plated in wells on a 24-well plate. When the cells
reached a confluence of 70%, transfection with FuGene HD
(Roche, Mannheim, Germany) was carried out according to
the manufacturer’s instructions. The ratio of the transfection
reagent to DNA was 2:3. Forty-eight hours after transfection,
the cells were washed three times with ice cold phosphate-
buffered saline (PBS; Invitrogen, Carlsbad, CA) and lysed in
150 lL of 1· passive lysis solution (Promega). Ten lL of
the protein extract was used for the dual luciferase assay
(Promega). The measurement of the firefly and the Renilla
luciferase activity was performed according to the manu-
facturer’s recommendations.
Electromobility shift assay (EMSA)
The proteins from nuclear extracts from HeLa, PCCL3,
and HEK cells were isolated as described previously (11).
The wild type as well as the mutant PAX8 promoter oligo
sequences were 5¢-end-labeled with IRD700 (Metabion,
Martinsried, Germany). The 10 lL binding reaction con-
tained 1 lg of protein, 10–50 nM oligo, 150 ng poly (dI-dC),
500 ng salmon sperm DNA, 5 mM DTT, 0.5% Tween20,
10 mM Tris, and 50 mM NaCl pH 7.5. The binding reaction
was incubated for 30 min at room temperature. Afterwards,
1 lL gel-loading buffer (containing 650 mg/mL sucrose,
0.3% OrangeG, 10 lM Tris pH 7.5, and 10 lM EDTA pH
8.0) was added, and the samples were loaded on a 4% native
polyacrylamide (PAA) gel. The PAA gel was supplemented
with 50 mM Tris pH 7.5, 200 mM glycine, 2 mM EDTA.
Towbin buffer (12) supplemented with 10 mM EDTA served
as a running buffer. Thereafter, the PAA gels were scanned
and visualized using the Odyssey Model 9120 and the
Odyssey v2.1 software (Li-Cor Biosciences, Bad Homburg,
Germany).
To test the protein binding capacity of the wild type and the
mutant promoter, the primers used for mutagenesis of
PAX8proWT and PAX8proMUT were labelled with an in-
frared dye (IRD700) and incubated with proteins of a nuclear
extract isolated from HeLa cells, PCCL3 cells, or HEK cells.
Results
Sequence analysis of the proposita’s genomic DNA re-
vealed a heterozygous mutation in the promoter sequence of
the PAX8 gene at position - 3 upstream of exon 1 (G >A).
This is 562 bp upstream of the translation start site in exon 2.
This mutation is located in a highly conserved area of the
PAX8 gene promoter (data not shown). It was not found in
100 normal alleles, making a common polymorphism un-
likely. The mutation was also found in a heterozygous state in
the mother of the proposita.
To study the consequence of the nucleotide substitution in
the PAX8 promoter region, both reporter constructs (PAX8-
proWT and PAX8proMUT) driving a luciferase reporter gene
were transiently transfected into HeLa, PCCL3, and HEK
cells respectively. Using 1 lg of plasmid DNA of each pro-
moter construct, a significant decrease of the luciferase ex-
pression was observed with the PAX8proMut construct
compared to the PAX8proWT in all three cell lines (Fig. 1).
We then investigated the ability of nuclear extracts from
HeLa, HEK, and PCCL3 cells to bind to the investigated
PAX8 promoter sequence. Neither the investigated wild type
promoter sequence nor the mutant PAX8 promoter sequence
showed a specific shift (Fig. 2), indicating that this sequence
is not important for specific protein binding.
Discussion
We report the case of a girl with DS who had CH attrib-
utable to thyroid hypoplasia associated with a heterozygous
FIG. 1. In vitro effects of the PAX8 promoter mutation.
Both PAX8 gene promoter constructs (PAX8proWT and
PAX8proMUT) were transiently transfected into PCCL3,
HEK, or HeLA cells. Using 1lg of plasmid DNA of each
promoter construct, a significant decrease of the luciferase
expression was observed with the PAX8proMut compared to
the PAX8proWT (dark black bar) in all three cell lines.
FIG. 2. Electromobility shift assay (EMSA) with nuclear
extracts from PCCL3 and PAX8proWT and PAX8proMUT.
Nuclear extracts isolated from PCCL3 cells were incubated
with double stranded (ds) oligonucleotides containing either
the wild type or the mutant PAX8 promoter sequence. No
specific protein binding to either double stranded oligo was
observed.
PAX8 PROMOTER DEFECT IN A CHILD WITH DOWN’S SYNDROME 941
mutation close to the transcription initiation site sequence of
the PAX8 promoter, which was inherited from the mother. In
our case, there was evidence of maternal Hashimoto’s disease
in that elevated TPO antibodies were detected in the infant
during the postnatal period, while the mother showed very
high TPO antibodies together with compensated primary
hypothyroidism (normal fT4 but elevated TSH) when the girl
was reevaluated at 3.5 years of age.
It is known that infants with DS commonly show TSH
elevations (9,10), which raises the possibility that the thyroid
dysfunction in our case could simply represent a nonspecific
effect of DS. Alternatively, it could be argued that the CH in
our patient resulted from transplacental transfer of maternal
thyroid antibodies.
Concerning the first point, it is true that TSH elevations
occur more commonly in DS, as for example when detected
by newborn screening, compared with the general population
(13,14). However, there is no evidence that the incidence of
the classic cause of true permanent CH—TD—is more
common in DS. Indeed, studies to date have shown the thy-
roid gland is neither ectopic nor absent in DS. Fort et al.
described the clinical characteristics of 11 DS newborns
detected by neonatal screening, none of whom had athyreosis
or thyroid ectopia (13). Moreover, a recent study of 13 fetuses
with DS by Luton et al. found no abnormality, including
goiter, on ultrasonography, although heterogeneity of the
glands and reduced follicular size on histology was found (15).
However, it should be noted that detailed, high-resolution
imaging of the thyroid in DS has not been carried out in a
prospective fashion, and hence mild alterations in size may
have previously gone undetected.
By contrast, it is well established that TSH levels tend to be
elevated in newborns with DS (9,10). Van Trotsenburg et al.
found a shift toward relatively higher TSH and lower fT4
levels in 97 placebo-treated infants with DS, while 99 DS
infants treated with levothyroxine needed relatively high fT4
concentrations to normalize TSH (16). This group concluded
that a type of mild, persistent CH occurs in DS, possibly
related to the genomic dosage imbalance of dosage-sensitive
genes interfering with thyroid hormone production. This
conjecture is supported by a recent study by Myerovitch
et al., who found a significant shift of the TSH distribution
curve to higher values compared with the general population
(17), and also of Luton et al., who found TSH elevations with
low fT4 levels yet no goiter in 6 of the 13 fetuses with DS
studied, indicating a degree of TSH resistance (15). Thus,
according to van Trotsenburg et al., many infants with DS
who are detected with raised TSH in the newborn period may
simply represent those at the extreme end of abnormal thy-
roid function parameters due to what can be regarded as a DS-
specific type of CH (16).
It is clear that our case is different from the model of TSH
resistance described above. The finding of actual thyroid
gland hypoplasia, with dysplastic features comprising cystic
changes on ultrasound, is not consistent with the thyroid
dysfunction associated with DS in the newborn period re-
ported previously. Similarly, transplacental transfer of ma-
ternal antibodies, while known to cause transient CH (18),
would not be expected to cause true, permanent CH as in our
case, in whom a significant TSH elevation ( > 50 mU/L) oc-
curred when the levothyroxine dose was reduced from 50 to
25 lg at three years of age.
It is our belief that the CH in our patient with DS is due to
the finding of a mutation in the PAX8 promoter. So far, two
monoallelic mutations in the PAX8 promoter region have
been described in individuals with TD (2,6), but in vitro
functional studies were only performed in one case (6). We
therefore decided to investigate whether the mutation at
position -3 found in our patient is pathogenic by per-
forming in vitro studies. As expected, the mutant PAX8 gene
promoter showed a significantly (25%) reduced ability to
activate a reporter gene compared to the wild type (Fig. 1).
This result is likely to be due to the fact that the mutant has
impact on the initiation of the transcriptional process (19).
This is because this part of the promoter sequence is rec-
ognized by the transcription initiation complex and is thus
important for proper binding of the DNA-dependent RNA
polymerase II (20). We therefore postulate that -3G > A is
very likely to be pathogenic, since this mutation falls di-
rectly into the conserved sequence of the transcription ini-
tiator element (21).
The fact that both the normal PAX8 promoter and the
mutant sequence did not bind specific nuclear proteins
present in PCCL3, HeLa, or HEK cells in our EMSA ex-
periments (Fig. 2) is not contradictory to our functional
studies of the promoter. This is because the double stranded
oligonucleotide investigated covers only a small part of the
promoter region. It is possible, therefore, that if a larger
piece of the transcriptional machinery had been investi-
gated, the altered sequence might have had an impact on the
binding of the transcriptional machinery in contrast to the
normal PAX8 promoter. We do not believe that the reduc-
tion in transcriptional activity, which we have found, is
caused by a thyroid specific factor, since we have observed
this not only in thyroid cells (PCCL3), but also in HEK and
HeLa cells. Work by Nitsch et al. supports our hypothesis,
since this group identified a thyroid-specific transcriptional
enhancer element 84 kb upstream of the PAX8 transcription
start site (22). Taken together, our in vitro findings suggest
that the altered promoter leads to reduced PAX8 gene ex-
pression, which is likely to be involved in the pathogenesis
of TD in our index patient.
The question arises as to why true permanent CH has
occurred in our index case with DS whereas the mother was
initially euthyroid, although she developed hypothyroidism
due to her Hashimoto’s disease. It is known that PAX8
mutations produce a highly variable phenotype (3,4,6,23–
25). It is therefore not surprising that the mother, who is also
a heterozygous carrier of the monoallelic PAX8 gene mu-
tation, was initially phenotypically normal. Our case is
similar to that of Congdon et al., who reported a girl with
CH in association with a eutopic hypoplastic thyroid gland,
who had a heterozygous transversion 119A–>C in exon 3 of
PAX8 replacing a conserved glutamine by proline in the
paired box domain (Q40P) (26). The child’s mother was also
heterozygous for this mutation but had a thyroid gland of
normal size and mild, adult-onset autoimmune hypothy-
roidism. It is of interest that the mothers in both our study
and the report by Congdon et al. had autoimmune hypo-
thyroidism, raising the possibility that a PAX8 alteration
might render the individual more prone to autoimmune
thyroid disease.
It remains unclear in what way this phenotypic vari-
ability is due to variable penetrance or expressivity of the
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mutant gene, or whether the genetic background plays a
role in this context. Moreover, haploinsufficiency, mono-
allelic expression, or imprinting could impact on the
phenotype (5).
It is possible that the CH related to a PAX8 mutation
that has been inherited from the mother was completely
independent of the child’s trisomy 21 in our case. If this is
so, our case serves to illustrate that CH, which has an
incidence of about 1 in 3000 births, may occur in DS just
as it does in the general population, and that infants with
DS and significant TSH elevations are entitled to the same
investigation, including thyroid imaging, as other infants
who are detected on newborn screening. However, it is
also possible that the genomic imbalance related to tri-
somy 21 in our patient may have resulted in a more severe
expression of the PAX8 gene mutation, which she had
inherited from her mother.
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